Autolus Therapeutics (AUTL) SVP Alex Driggs reports equity stake
Rhea-AI Filing Summary
Autolus Therapeutics plc executive Alex Driggs, SVP Legal Affairs and General Counsel, reports his initial ownership in the company. He directly holds 18,418 American Depositary Shares, plus multiple share options over ADSs with exercise prices ranging from $1.62 to $29.86 expiring between 2028 and 2036, and 33,000 restricted share units that vest in four equal annual installments starting in 2027.
Positive
- None.
Negative
- None.
Insider Trade Summary
13 transactions reported
Mixed
13 txns
Insider
Driggs Alex
Role
SVP, Legal Affairs and GC
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | American Depositary Shares | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Restricted Share Units | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
American Depositary Shares — 18,418 shares (Direct);
Share Option (right to buy) — 729,400 shares (Direct);
Restricted Share Units — 33,000 shares (Direct)
Footnotes (10)
- F1. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share.
- F2. Fully vested and exercisable.
- F3. This option vested 25% on July 22, 2023 and the remainder vests in 36 equal monthly installments thereafter.
- F4. This option vested 25% on March 6, 2024 and the remainder vests in 36 equal monthly installments thereafter.
- F5. This option vested 25% on October 12, 2024 and the remainder vests in 36 equal monthly installments thereafter.
- F6. This option vested 25% on February 23, 2025 and the remainder vests in 36 equal monthly installments thereafter.
- F7. This option vested 25% on March 14, 2026 and the remainder vests in 36 equal monthly installments thereafter.
- F8. This option vests 25% on March 4, 2027 and the remainder vests in 36 equal monthly installments thereafter.
- F9. The restricted share units ("RSUs") vest in four equal annual installments commencing on January 26, 2027.
- F10. Each RSU represents a contingent right to receive one Issuer American Depositary Share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider position does Alex Driggs hold at Autolus Therapeutics (AUTL)?
Alex Driggs is SVP, Legal Affairs and General Counsel at Autolus Therapeutics. The filing identifies him as an officer, not a director or 10% owner, and discloses his personal equity holdings in the company’s American Depositary Shares and related equity awards.
How many Autolus Therapeutics (AUTL) ADSs does Alex Driggs directly own?
Alex Driggs directly owns 18,418 American Depositary Shares of Autolus Therapeutics. Each ADS is convertible at any time, at his option, into one ordinary share of the company, giving him equivalent exposure to 18,418 ordinary shares through this holding.
Do the RSUs and options reported by Alex Driggs in AUTL convert into ADSs?
Yes, both the RSUs and options reported are linked to Autolus ADSs. Each RSU corresponds to one ADS upon settlement, and each share option provides a right to buy ADSs at a fixed exercise price, subject to the applicable vesting and expiration terms described.
Does the Autolus Therapeutics (AUTL) Form 3 show any insider buying or selling by Alex Driggs?
The Form 3 lists Alex Driggs’s existing holdings but no purchases or sales. All entries are categorized as holdings, with no buy or sell transaction codes, reflecting his initial statement of beneficial ownership rather than new market activity.